Our aim was to systematically review the prevalence of body dysmorphic disorder (BDD) in a variety of settings. Weighted prevalence estimate and 95% confidence intervals in each study were calculated. The weighted prevalence of BDD in adults in the community was estimated to be 1.9%; in adolescents 2.2%; in student populations 3.3%; in adult psychiatric inpatients 7.4%; in adolescent psychiatric inpatients 7.4%; in adult psychiatric outpatients 5.8%; in general cosmetic surgery 13.2%; in rhinoplasty surgery 20.1%; in orthognathic surgery 11.2%; in orthodontics/cosmetic dentistry settings 5.2%; in dermatology outpatients 11.3%; in cosmetic dermatology outpatients 9.2%; and in acne dermatology clinics 11.1%. Women outnumbered men in the majority of settings but not in cosmetic or dermatological settings. BDD is common in some psychiatric and cosmetic settings but is poorly identified.

The ICD-11 classification of personality disorder yields somewhat higher levels of personality dysfunction than ICD-10, possibly because the age range for the onset of diagnosis is now flexible. The range of severity levels make the classification more useful than ICD-10 in clinical practice as it identifies the greater pathology necessary for intervention.

Hyperprolactinemia is a common consequence of treatment with an antipsychotic medication. It can result in hypogonadism due to the inhibitory effect of elevated prolactin levels on the hypothalamic-pituitary-gonadal hormonal axis. We present a case of hypogonadism secondary to hyperprolactinemia in a patient taking antipsychotic medication, with radiological evidence of a pituitary microadenoma. The relevance and investigation of hyperprolactinemia in patients being treated with antipsychotic medications are discussed.

Background: Much of the literature on psychiatric intensive care units (PICU) examines either the treatment a patient receives or the unit's readmission rates. There is currently a lack of research into length of stay and patients' post-discharge outcomes or follow-up studies. Aims: This study explored the care pathway and patient outcomes six weeks post-discharge. Through examining patient care pathways, it was also possible to compare the length of stay at a female PICU against the Department of Health's guidance. Method: Patient data from internal records were gathered for patients who stayed at a South London PICU between October 2014 and March 2015; this equated to 50 female patient records. Results: At discharge, 86% of patients went to general acute treatment settings, 6% to home treatment teams, 4% to forensic services, 2% to a mother and baby unit and 2% to a private acute bed. At six weeks postdischarge 4% of patients had returned to the PICU, 52% were in the community, 36% were in acute treatment settings and 4% were absent without leave. Three patients exceeded the Department of Health's recommended maximum length of stay. Conclusions: The current care pathway appears to be successful in returning patients to the community within six weeks. Within the follow-up period over half of the patients had returned home, whilst a third were in general acute treatment settings.